This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Merck probe over Remicade closed, but CMA warns over drug discounting

( March 14, 2019, 13:51 GMT | Official Statement) -- MLex Summary: An antitrust probe into a suspected anticompetitive discount scheme by drugmaker Merck Sharp & Dohme has been closed by the Competition and Markets Authority after it found no grounds for action. The CMA said MSD’s discount mechanism was not, in practice, likely to limit competition because the market worked differently when it was introduced to what MSD had envisaged when it was designed. The regulator had initially found it was designed to delay or reduce competition from other suppliers of MSD’s infliximab product Remicade, used to treat chronic illnesses such as Crohn’s disease and rheumatoid arthritis. The CMA has, however, warned drug makers over price-discounting schemes.Statement follows. The document is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections